about
The human homologue of unc-93 maps to chromosome 6q27 - characterisation and analysis in sporadic epithelial ovarian cancer.Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancerGenomic aberrations in borderline ovarian tumors.Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer.Molecular genetic analysis of ovarian serous cystadenomas.Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop.Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitorsSporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.Evaluation of FHIT gene alterations in ovarian cancerBenign epithelial ovarian tumours-cancer precursors or markers for ovarian cancer risk?Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinomaDecreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomasReduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2Identification of exons in a region of human chromosome 6q known to contain tumour suppressor genes.Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesisHigh prevalence of codon 213Arg-->Stop mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands.Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice.Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers.Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
P2860
Q24311419-902E50A5-2163-40DE-8BF8-FEAF86979DB8Q24656704-06F50E34-C9BE-48E8-B5AD-F5CFA26D1146Q33728834-491D0DC5-A63F-417C-B106-502E5C4A2C0BQ33919065-EE43263D-1174-41A4-9012-5D6F311E56AFQ34112191-85E271C5-8DB8-4247-B967-4D0591A1E90DQ34312494-0038388D-5AB4-4D93-A676-420CDB8FDF59Q34579904-CA3E4122-BF1C-4CEB-8B0D-94D71A1E4DA4Q35098091-B2BD6A94-500C-4A03-A25B-1E22762DD68CQ35831995-DFA2F67B-33CA-4610-B2DD-8C14DA534741Q36114881-F182A27B-16CD-4FC0-BEF7-E608681106ADQ36140990-06C5FB43-50DE-42BF-A706-6A22888DF24EQ36292325-4B921AAC-1E56-4872-9A7F-21784C5122EEQ36457913-49CA5B37-AAD1-4D87-903B-A9D4550AB9E5Q36615915-5B3F6A5B-4231-4123-9CF9-DC981D9E2494Q36622573-7A2E239E-3B7B-4CF3-808D-7C67A068E233Q36643987-C12A3BB7-850B-41A6-AA68-3E50A0FED4F5Q36849843-9F17CC33-DC35-47AB-B6CE-B9A1DFD4FCF5Q36868408-B90CD3DF-58AF-4D52-8EC7-4B486E9B2F7AQ36896602-32815314-282E-4EFA-B707-F3646C13CB12Q37101060-2A01B187-C790-4462-8C47-B2A6BA231980Q38723863-E402C09A-AA16-489C-B181-E928A18192F5Q41055625-AFEEBD19-992C-4487-990E-3B4BBF8A123AQ47794474-CCFCEB12-DD10-4F33-88C6-D38631732660
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
The genetic analysis of ovarian cancer.
@ast
The genetic analysis of ovarian cancer.
@en
type
label
The genetic analysis of ovarian cancer.
@ast
The genetic analysis of ovarian cancer.
@en
prefLabel
The genetic analysis of ovarian cancer.
@ast
The genetic analysis of ovarian cancer.
@en
P2093
P2860
P356
P1476
The genetic analysis of ovarian cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1995.367
P407
P577
1995-09-01T00:00:00Z